Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single-dose escalation study of LY2878735 with PET SERT occupancy assessment
NL-OMON34991Phase 1Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY2878735 in Visceral pain (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Pharmacodynamics, Pharmacokinetics and 2 more. Started Feb 2010; status: active, not recruiting.
02
Drugs
LY2878735
03
Conditions
Visceral pain
Beyond the preview
Go deeper on NL-OMON34991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34991.